TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06305234: A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

Sponsor: BioMarin Pharmaceutical · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,207,500

Rescue Site Savings

+$793,500

Unlock Full NCT06305234 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06305234 Rescue Dossier →